-
公开(公告)号:US11713356B2
公开(公告)日:2023-08-01
申请号:US16754285
申请日:2018-10-15
发明人: Nicolas Poirier , Caroline Mary , Bernard Vanhove
CPC分类号: C07K16/2896 , A61K35/17 , A61K39/3955 , A61K45/06 , A61P35/00 , C07K16/2827 , C07K16/2878 , A61K2039/507 , C07K2317/24 , C07K2317/565 , C07K2317/74 , C07K2317/76 , C07K2317/92
摘要: The present invention provides new modified anti-SIRPa antibodies linked to an immunotherapeutic agent which are bifunctional and able to specifically enhance the immune response and uses thereof.
-
公开(公告)号:US20230340133A1
公开(公告)日:2023-10-26
申请号:US17941885
申请日:2022-09-09
发明人: Nicolas Poirier , Caroline Mary , Bernard Vanhove
CPC分类号: C07K16/2866 , G01N33/5041 , G01N33/6854 , A61K2039/505
摘要: The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127. According to another aspect of the invention antibodies are provided which recognize a human CD127 epitope comprising sequences from the 2b site of CD127, in particular the epitope comprising comprises the human CD127 sequences of domain D1 and of the 2b site of CD127, in particular the epitope comprises at least one sequence from D1 comprising SEQ ID No: 115 (in particular comprising SEQ ID No: 110) and/or SEQ ID No: 111 and/or a sequence from the 2b site comprising the sequence of SEQ ID No: 116 and optionally also comprises SEQ ID No: 117 (in particular comprises SEQ ID No: 111). The antibodies of the invention are suitable for use in order to remedy to a condition diagnosed in a human patient which results from pathogenesis related to lymphopoiesis, when IL-7 signalling pathways provide contribution to said pathogenesis, especially when an increase in the maturation, more precisely the upregulation of costimulatory molecules, of dendritic cells is undesirable.
-
公开(公告)号:US11230602B2
公开(公告)日:2022-01-25
申请号:US16080572
申请日:2017-02-28
发明人: Nicolas Poirier , Caroline Mary
摘要: The description concerns humanized antibodies directed against the extracellular domain of the alpha chain of the receptor for interleukin-7 (IL-7), especially against the receptor for human IL-7 expressed on human cells (also designated human IL-7Ralpha or IL-7Ra or CD127) and which do not interfere with the IL-7 or TSLP signaling pathways. The antibodies described do not have an antagonistic effect on the IL-7 receptor, but may still present cytotoxic activity against CD127 positive cells. In a particular embodiment, the antibody does not have an agonist effect on the IL-7 receptor.
-
公开(公告)号:US20170166643A1
公开(公告)日:2017-06-15
申请号:US15416513
申请日:2017-01-26
发明人: Bernard Vanhove , Caroline Mary , Flora Coulon
IPC分类号: C07K16/28
摘要: The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.
-
公开(公告)号:US11279766B2
公开(公告)日:2022-03-22
申请号:US16093062
申请日:2017-04-14
发明人: Nicolas Poirier , Caroline Mary , Bernard Vanhove , Vanessa Gauttier , Virginie Thepenier , Sabrina Pengam
摘要: The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.
-
公开(公告)号:US10689444B2
公开(公告)日:2020-06-23
申请号:US15416513
申请日:2017-01-26
发明人: Bernard Vanhove , Caroline Mary , Flora Coulon
摘要: The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.
-
公开(公告)号:US20240084019A1
公开(公告)日:2024-03-14
申请号:US17767606
申请日:2020-10-09
CPC分类号: C07K16/2866 , A61P35/00 , A61P37/06
摘要: The present invention provides humanized anti-CMKLR1 compounds having an agonist capability on the interaction between Resolvin E1 and CMKLR1, and their uses for treating or preventing a disease, in particular wherein the resolution of inflammation is delayed or disrupted.
-
公开(公告)号:US11926671B2
公开(公告)日:2024-03-12
申请号:US17363260
申请日:2021-06-30
CPC分类号: C07K16/2866 , C07K16/244 , C07K2317/14 , C07K2317/24 , C07K2317/76 , C07K2317/92
摘要: The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.
-
公开(公告)号:US11352430B2
公开(公告)日:2022-06-07
申请号:US17414967
申请日:2019-12-17
摘要: Described herein are humanized anti-PD-1 antibodies, nucleic acids encoding such, and uses thereof in enhancing immune responses by activating T cells and treating diseases such as cancer and an infectious disease.
-
公开(公告)号:US11884723B2
公开(公告)日:2024-01-30
申请号:US16979627
申请日:2019-03-13
CPC分类号: C07K16/2803 , A61K45/06 , C07K2317/565 , C07K2317/76
摘要: The invention is in the field of immunotherapy. The present invention provides antibodies useful in therapeutic and diagnostic applications targeting human SIRPa, said antibodies enhancing the cross-presentation of antigens to T cells. The invention also provides antibodies against specific isoforms of SIRP a and able to disrupt the interaction between those isoforms of SIRP a and human CD47 for use in treating or preventing a disease, or diagnostic applications, and methods for producing and/or selecting anti-human SIRPa antibodies that bind with different affinities to various isoforms of human SIRP members.
-
-
-
-
-
-
-
-
-